Drugs / Peptide loaded dendritic cell vaccine
Peptide loaded dendritic cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03300843 | Apr 2018 → Jul 2019 | breast cancer, malignant pancreatic neoplasm, melanoma, ovarian cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide loaded dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300843 ↗ |
| Modality | Cell therapy | “autologous mature dendritic cells loaded with long peptides and minimal epitopes” NCT03300843 ↗ |
| Route | Intravenous | “administered intravenously and subcutaneously” NCT03300843 ↗ |
| Route | Subcutaneous | “administered intravenously and subcutaneously” NCT03300843 ↗ |